Cite
Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial.
MLA
Kauf, Teresa L., et al. “Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, Is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial.” The Journal of Urology, vol. 191, no. 6, June 2014, pp. 1721–27. EBSCOhost, https://doi.org/10.1016/j.juro.2013.12.015.
APA
Kauf, T. L., Svatek, R. S., Amiel, G., Beard, T. L., Chang, S. S., Fergany, A., Karnes, R. J., Koch, M., O’Hara, J., Lee, C. T., Sexton, W. J., Slaton, J. W., Steinberg, G. D., Wilson, S. S., Techner, L., Martin, C., Moreno, J., & Kamat, A. M. (2014). Alvimopan, a peripherally acting μ-opioid receptor antagonist, is associated with reduced costs after radical cystectomy: economic analysis of a phase 4 randomized, controlled trial. The Journal of Urology, 191(6), 1721–1727. https://doi.org/10.1016/j.juro.2013.12.015
Chicago
Kauf, Teresa L, Robert S Svatek, Gilad Amiel, Timothy L Beard, Sam S Chang, Amr Fergany, R Jeffrey Karnes, et al. 2014. “Alvimopan, a Peripherally Acting μ-Opioid Receptor Antagonist, Is Associated with Reduced Costs after Radical Cystectomy: Economic Analysis of a Phase 4 Randomized, Controlled Trial.” The Journal of Urology 191 (6): 1721–27. doi:10.1016/j.juro.2013.12.015.